• 1
    Kearney PM, Whelton M, Reynolds K, et al.Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:1119.
  • 2
    Stason WB. Hypertension: a policy perspective, 1976–2008. J Am Soc Hypertens. 2009;3:113118.
  • 3
    Mancia G, De Backer G, Dominiczak A, et al.2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens. 2007;25:17511762.
  • 4
    Chobanian AV, Bakris GL, Black HR, et al.Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:12061252.
  • 5
    Black HR. Triple fixed-dose combination therapy: back to the past. Hypertension. 2009;54:1922.
  • 6
    Gradman AH, Basile JN, Carter BL, et al.Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:9098.
  • 7
    Mourad J-J, Waeber B, Zannad F, et al.Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens. 2004;22:23792386.
  • 8
    Wald DS, Law M, Morris JK, et al.Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290300.
  • 9
    Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004;116(suppl 5A):30S38S.
  • 10
    Borenstein M, Hedges LV, Higgins J, Rothstein H. Introduction to Meta-Analysis. Hoboken, NJ: John Wiley & Sons Inc; 2009.
  • 11
    Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol. 2000;53:207216.
  • 12
    Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455463.
  • 13
    Moher D, Liberati A, Tetzlaff J, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535b2535.
  • 14
    Liberati A, Altman DG, Tetzlaff J, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700b2700.
  • 15
    Fogari R, Zoppi A, Derosa G, et al.Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21:220224.
  • 16
    Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide. Hypertension. 2009;54:3239.
  • 17
    Oparil S, Melino M, Lee J, et al.Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32:12521269.
  • 18
    Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399407.
  • 19
    Jamerson K, Weber MA, Bakris GL, et al.Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;23:24172428.
  • 20
    Gilbody SM, Song F, Eastwood AJ, Sutton A. The causes, consequences and detection of publication bias in psychiatry. Acta Psychiatr Scand. 2000;102:241249.
  • 21
    Weir MR, Hsueh WA, Nesbitt SD, et al.A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens (Greenwich).2011;13:404412.
  • 22
    Calhoun DA, Crikelair NA, Yen J, Glazer RD. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety. Adv Therapy.2009;26:10121023.
  • 23
    Lacourcière Y, Crikelair N, Glazer RD, et al.24-hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011;25:615622.
  • 24
    Wright RF, Duprez D, Purkayastha D, et al.Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study. J Clin Hypertens (Greenwich).2011;13:588597.
  • 25
    Duprez D, Ferdinand K, Purkayastha D, et al.Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. Vasc Health Risk Manag.2011;7:701708.
  • 26
    Destro M, Luckow A, Samson M, et al.Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens.2008;2:294302.
  • 27
    Destro M, Crikelair N, Yen J, Glazer R. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vasc Health Risk Manag.2010;6:821827.
  • 28
    Allemann Y, Fraile B, Lambert M, et al.Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich).2008;10:185194.
  • 29
    Allemann Y, Crikelair N, Yen J, Glazer R. Achieving target Bp with the addition of Hctz to amlodipine/valsartan in hypertensive patients: Pp.5.212. J Hypertens. 2010;28:e112.
  • 30
    Flack JM, Calhoun DA, Satlin L, et al.Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009;23:479489.
  • 31
    Oparil S, Giles T, Ofili EO, et al.Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. J Hypertens. 2011;29:161170.
  • 32
    Oparil S, Giles T, Ofili E, et al.Intensive treatment with combination amlodipine/valsartan provides greater efficacy vs moderate treatment for hypertensive patients uncontrolled on Arb monotherapy: the Extra Study: Pp.5.208. J Hypertens. 2010;28:e110e111.
  • 33
    Giles T, Oparil S, Ofili E, et al.Intensive dose of combination amlodipine/valsartan provides improved 24-H Bp response compared to moderate dose in hypertensive patients uncontrolled on Arb monotherapy: Pp.5.211. J Hypertens. 2010;28:e112.
  • 34
    Fogari R, Zoppi A, Mugellini A, et al.Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. Expert Opin Pharmacother. 2012;13:629636.
  • 35
    Ram CV, Sachson R, Littlejohn T, et al.Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Am J Cardiol. 2011;107:13461352.
  • 36
    Izzo JL Jr, Chrysant SG, Kereiakes DJ, et al.24-hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. J Clin Hypertens (Greenwich).2011;13:873880.
  • 37
    White WB, Calhoun DA, Samuel R, et al.Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? The valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich).2008;10:450458.